See Hexima's Chief Science Officer, Prof Marilyn Anderson, talking about our new treatment for toenail fungus in this new video by the Australian Academy of Science.
Presentations and Results from the 2017 Hexima Limited Annual General Meeting held 21st November 2017
Hexima Limited is pleased to announce today that it has received Human Research Ethics Committee approval to conduct a phase 1/2a clinical trial of HXP124 in patients with fungal nail infections.
Hexima’s CEO Dr Nicole van der Weerden said “Obtaining ethics approval for our first clinical trial is a major milestone for Hexima. It is the culmination of the last three years of work to generate the required non-clinical data including preclinical safety/toxicology, efficacy testing and manufacture, formulation and stability of HXP124. The ethics committee has reviewed this data, along with our clinical study design, and granted us permission to test this molecule on human patients for the first time. This is a critical step forward in the development of HXP124 as a treatment for fungal nail infections and we are very excited to begin this next phase of development.”
NOTICE IS GIVEN that the Annual General Meeting of the ordinary shareholders of Hexima Limited ABN 64 079 319 314 (“Company”) will be held at KPMG, Level 36, Tower 2, Collins Square, 727 Collins Street, Melbourne, Victoria on Tuesday 21 November 2017 at 11am.
Hexima Annual Financial Report for the year ended June 30 2017
Closing Share Price at 30 June 2017
Shareholders are invited to attend a presentation by Hexima CEO Dr Nicole van der Weerden. To view a copy of the presentation click here.
Upcoming Event: Tuesday 25th July at 11.30am at Lvl 38, 88 Phillip Street Sydney (offices of Bell Potter).
Hexima is pleased to advise that it has completed a pivotal GLP repeat-dose dermal irritation study in minipigs for HPX124 which should provide sufficient pre-clinical animal toxicology data to support a first-in-human clinical trial for HXP124 as a treatment of onychomycosis. Further details are provided in the presentation.
Hexima commences research into application of plant defensin technology in Candidaemias and Candida-based biofilms
Hexima is pleased to announce the commencement of a project to assess the application of Hexima’s antifungal technology in control of medically important Candidaemias and Candida-based biofilms. Systemic Candida infections are a major problem in immunocompromised...